Jason Rhodes Sells 426,412 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 426,412 shares of the business’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $26.20, for a total value of $11,171,994.40. Following the sale, the director owned 751,411 shares of the company’s stock, valued at approximately $19,686,968.20. The trade was a 36.20% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Price Performance

Dyne Therapeutics stock opened at $26.00 on Wednesday. The business has a 50-day moving average of $23.18 and a 200-day moving average of $19.61. The company has a current ratio of 12.02, a quick ratio of 12.02 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $4.86 billion, a P/E ratio of -7.81 and a beta of 1.07. Dyne Therapeutics, Inc. has a 1 year low of $11.65 and a 1 year high of $27.31.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). On average, equities analysts anticipate that Dyne Therapeutics, Inc. will post -3.37 EPS for the current year.

Institutional Investors Weigh In On Dyne Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Hilton Head Capital Partners LLC bought a new position in Dyne Therapeutics during the 1st quarter valued at $26,000. Strs Ohio bought a new position in Dyne Therapeutics during the fourth quarter valued at $51,000. Allworth Financial LP purchased a new stake in Dyne Therapeutics during the second quarter valued at about $62,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Dyne Therapeutics during the 4th quarter valued at approximately $84,000. Finally, Steward Partners Investment Advisory LLC raised its stake in shares of Dyne Therapeutics by 102.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after purchasing an additional 2,465 shares during the period. Institutional investors own 96.68% of the company’s stock.

Wall Street Analyst Weigh In

DYN has been the subject of several analyst reports. Wall Street Zen cut shares of Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 1st. TD Cowen began coverage on Dyne Therapeutics in a research report on Friday, June 26th. They issued a “buy” rating on the stock. Sanford C. Bernstein raised their price target on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Cantor Fitzgerald assumed coverage on shares of Dyne Therapeutics in a research report on Thursday, July 23rd. They issued an “overweight” rating on the stock. Finally, Morgan Stanley dropped their price target on Dyne Therapeutics from $47.00 to $45.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $34.42.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.